Patents Assigned to Medarex
  • Publication number: 20090214544
    Abstract: Methods for treating lymphomas characterized by expression of CD30 using anti-CD30 antibodies and steroids in combination are disclosed.
    Type: Application
    Filed: April 25, 2006
    Publication date: August 27, 2009
    Applicant: MEDAREX
    Inventors: Steven Fischkoff, Michael Yellin
  • Patent number: 6096311
    Abstract: Monoclonal antibodies which react specifically to Fc receptor of human effector cells are disclosed. Binding of the antibodies to the receptor is not blocked by human immunoglobulin G. The antibodies are useful for targeting human effector cells (e.g. macrophages) against a target cell (e.g. a cancer cell, an infectious agent, etc.) For this purpose, bifunctional antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc receptor antibody and the binding region of a target-specific antibody. Targeted effector cells can be used to kill target cells by cell mediated antibody dependent cytolysis.
    Type: Grant
    Filed: June 2, 1997
    Date of Patent: August 1, 2000
    Assignee: Medarex
    Inventors: Michael W. Fanger, Paul M. Guyre, Clark L. Anderson